RESPImmun Publications

Full papers/articles (Journals):

2023

Jandl K, Radic N, Zeder K, Kovacs G, Kwapiszewska G: Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target. Pharmacol Ther, 2023; 247:108438.

Mutgan AC, Jandl K, Radic N, Valzano F, Kolb D, Hoffmann J, Foris V, Wilhelm J, Boehm PM, Hoetzenecker K, Olschewski A, Olschewski H, Heinemann A, Wygrecka M, Marsh LM, Kwapiszewska G: Pentastatin, a matrikine of the collagen IVαα5, is a novel endogenous mediator of pulmonary endothelial dysfunction. Am J Physiol Cell Physiol, 2023; 325(5):C1294–C1312.

Rani A, Marsche G: A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease. Pharmaceutics, 2023; 15(5):1504.

Rajesh R, Atallah R, Bärnthaler T: Dysregulation of metabolic pathways in pulmonary fibrosis. Pharmacol Therv, 2023; 246:108436.

Myronenko O, Foris V, Crnkovic S, Olschewski A, Rocha S, Nicolls MR, Olschewski H: Endotyping COPD: hypoxia-inducible factor-2 as a molecular "switch" between the vascular and airway phenotypes? Eur Respir Rev, 2023; 32(167):220173.

2022

Stadler JT, Mangge H, Rani A, Curcic P, Herrmann M, Prüller F, Marsche G: Low HDL Cholesterol Efflux Capacity Indicates a Fatal Course of COVID-19. Antioxidants, 2022; 11(10):1858.

Sinha M, Zabini D, Guntur D, Nagaraj C, Enyedi P, Olschewski H, Kuebler WM, Olschewski A: Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis. Pharmacol Ther, 2022; 237:108249.